JP2002540814A

JP2002540814A - 転移性前立腺腫瘍の診断および処置のための方法

転移性前立腺腫瘍の診断および処置のための方法

Info

Publication number: JP2002540814A
Authority: JP; Japan
Prior art keywords: flt; prostate; cells; expression; vegf
Prior art date: 1999-04-13
Legal status : Pending

Application number

JP2000611075A

Other languages

English (en)

Japanese (ja)

Other versions

JP2002540814A5 (enExample

Inventor

サイエル．ス，

Original Assignee

ノースウエストバイオセラピューティクス，インコーポレイティド

Priority date

1999-04-13

Filing date

1999-04-13

Publication date

2002-12-03

1999-04-13 Application filed by ノースウエストバイオセラピューティクス，インコーポレイティド filed Critical ノースウエストバイオセラピューティクス，インコーポレイティド

2002-12-03 Publication of JP2002540814A publication Critical patent/JP2002540814A/ja

2006-06-22 Publication of JP2002540814A5 publication Critical patent/JP2002540814A5/ja

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 163
208000023958 prostate neoplasm Diseases 0.000 title claims abstract description 32
206010061289 metastatic neoplasm Diseases 0.000 title claims abstract description 29
230000001394 metastastic effect Effects 0.000 title claims abstract description 28
238000003745 diagnosis Methods 0.000 title description 3
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims abstract description 364
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims abstract description 355
210000004027 cell Anatomy 0.000 claims abstract description 183
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims abstract description 130
108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims abstract description 102
230000027455 binding Effects 0.000 claims abstract description 86
230000000694 effects Effects 0.000 claims abstract description 74
206010027476 Metastases Diseases 0.000 claims abstract description 40
210000002307 prostate Anatomy 0.000 claims abstract description 34
230000009401 metastasis Effects 0.000 claims abstract description 30
238000012216 screening Methods 0.000 claims abstract description 25
230000002401 inhibitory effect Effects 0.000 claims abstract description 21
102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims description 126
108090000623 proteins and genes Proteins 0.000 claims description 118
150000007523 nucleic acids Chemical class 0.000 claims description 101
210000005267 prostate cell Anatomy 0.000 claims description 96
102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 claims description 94
102000039446 nucleic acids Human genes 0.000 claims description 94
108020004707 nucleic acids Proteins 0.000 claims description 94
102000004169 proteins and genes Human genes 0.000 claims description 83
206010060862 Prostate cancer Diseases 0.000 claims description 60
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 60
239000012634 fragment Substances 0.000 claims description 59
239000003550 marker Substances 0.000 claims description 49
238000003556 assay Methods 0.000 claims description 48
239000002773 nucleotide Substances 0.000 claims description 46
125000003729 nucleotide group Chemical group 0.000 claims description 46
108091034117 Oligonucleotide Proteins 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 31
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 25
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 25
206010028980 Neoplasm Diseases 0.000 claims description 21
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 21
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 21
239000003112 inhibitor Substances 0.000 claims description 21
238000001514 detection method Methods 0.000 claims description 20
239000003446 ligand Substances 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 17
239000000074 antisense oligonucleotide Substances 0.000 claims description 16
238000012230 antisense oligonucleotides Methods 0.000 claims description 16
210000001124 body fluid Anatomy 0.000 claims description 13
230000000295 complement effect Effects 0.000 claims description 12
239000010839 body fluid Substances 0.000 claims description 11
230000002860 competitive effect Effects 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 10
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 8
208000010658 metastatic prostate carcinoma Diseases 0.000 claims description 8
210000004369 blood Anatomy 0.000 claims description 7
239000008280 blood Substances 0.000 claims description 7
238000004393 prognosis Methods 0.000 claims description 7
101710120463 Prostate stem cell antigen Proteins 0.000 claims description 6
102100036735 Prostate stem cell antigen Human genes 0.000 claims description 6
108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 6
102100038358 Prostate-specific antigen Human genes 0.000 claims description 6
102000057032 Tissue Kallikreins Human genes 0.000 claims description 6
108700022175 Tissue Kallikreins Proteins 0.000 claims description 6
238000000684 flow cytometry Methods 0.000 claims description 6
210000000582 semen Anatomy 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 5
210000002700 urine Anatomy 0.000 claims description 4
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 3
102000013563 Acid Phosphatase Human genes 0.000 claims description 3
108010051457 Acid Phosphatase Proteins 0.000 claims description 3
238000010166 immunofluorescence Methods 0.000 claims description 3
238000012544 monitoring process Methods 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 2
PCNLLVFKBKMRDB-UHFFFAOYSA-N N-ethyl-N-[[2-(1-pentylindol-3-yl)-1,3-thiazol-4-yl]methyl]ethanamine Chemical compound C(C)N(CC=1N=C(SC=1)C1=CN(C2=CC=CC=C12)CCCCC)CC PCNLLVFKBKMRDB-UHFFFAOYSA-N 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 30
229940124597 therapeutic agent Drugs 0.000 abstract description 20
230000015572 biosynthetic process Effects 0.000 abstract description 19
108020003175 receptors Proteins 0.000 abstract description 12
230000012010 growth Effects 0.000 abstract description 10
102000005962 receptors Human genes 0.000 abstract description 10
230000005764 inhibitory process Effects 0.000 abstract description 7
230000001413 cellular effect Effects 0.000 abstract description 2
230000003511 endothelial effect Effects 0.000 abstract description 2
210000004881 tumor cell Anatomy 0.000 abstract description 2
230000002792 vascular Effects 0.000 abstract description 2
102100038232 Vascular endothelial growth factor C Human genes 0.000 abstract 2
102100038234 Vascular endothelial growth factor D Human genes 0.000 abstract 2
235000018102 proteins Nutrition 0.000 description 75
230000004568 DNA-binding Effects 0.000 description 49
241000282414 Homo sapiens Species 0.000 description 44
108700008625 Reporter Genes Proteins 0.000 description 43
108020001507 fusion proteins Proteins 0.000 description 36
102000037865 fusion proteins Human genes 0.000 description 36
230000000692 anti-sense effect Effects 0.000 description 31
238000013518 transcription Methods 0.000 description 31
230000035897 transcription Effects 0.000 description 31
230000004913 activation Effects 0.000 description 29
239000013612 plasmid Substances 0.000 description 26
240000004808 Saccharomyces cerevisiae Species 0.000 description 24
230000004927 fusion Effects 0.000 description 24
239000000523 sample Substances 0.000 description 24
102100039556 Galectin-4 Human genes 0.000 description 22
238000001415 gene therapy Methods 0.000 description 22
108020004414 DNA Proteins 0.000 description 21
239000013598 vector Substances 0.000 description 20
230000009918 complex formation Effects 0.000 description 19
230000003993 interaction Effects 0.000 description 19
210000001519 tissue Anatomy 0.000 description 19
241001465754 Metazoa Species 0.000 description 16
108090000765 processed proteins & peptides Proteins 0.000 description 16
210000005253 yeast cell Anatomy 0.000 description 16
238000009396 hybridization Methods 0.000 description 15
238000012360 testing method Methods 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 14
210000000130 stem cell Anatomy 0.000 description 14
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 13
238000003018 immunoassay Methods 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 13
108091028043 Nucleic acid sequence Proteins 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
210000003958 hematopoietic stem cell Anatomy 0.000 description 12
101150050575 URA3 gene Proteins 0.000 description 11
239000000427 antigen Substances 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
201000011510 cancer Diseases 0.000 description 11
238000005516 engineering process Methods 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
210000001165 lymph node Anatomy 0.000 description 11
230000013011 mating Effects 0.000 description 11
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 11
239000012190 activator Substances 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000003752 polymerase chain reaction Methods 0.000 description 10
239000000047 product Substances 0.000 description 10
241000894007 species Species 0.000 description 10
108091026890 Coding region Proteins 0.000 description 9
108010001515 Galectin 4 Proteins 0.000 description 9
238000010171 animal model Methods 0.000 description 9
238000002744 homologous recombination Methods 0.000 description 9
230000006801 homologous recombination Effects 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
101150066555 lacZ gene Proteins 0.000 description 9
108091006106 transcriptional activators Proteins 0.000 description 9
241000588724 Escherichia coli Species 0.000 description 8
101150009006 HIS3 gene Proteins 0.000 description 8
101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 8
210000001744 T-lymphocyte Anatomy 0.000 description 8
230000021615 conjugation Effects 0.000 description 8
238000009472 formulation Methods 0.000 description 8
239000002609 medium Substances 0.000 description 8
230000004850 protein–protein interaction Effects 0.000 description 8
230000001177 retroviral effect Effects 0.000 description 8
241000701161 unidentified adenovirus Species 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 7
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 7
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 7
239000005557 antagonist Substances 0.000 description 7
230000003305 autocrine Effects 0.000 description 7
239000011616 biotin Substances 0.000 description 7
229960002685 biotin Drugs 0.000 description 7
235000020958 biotin Nutrition 0.000 description 7
239000002771 cell marker Substances 0.000 description 7
239000002299 complementary DNA Substances 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
230000006870 function Effects 0.000 description 7
210000004408 hybridoma Anatomy 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
101100372770 Homo sapiens FLT4 gene Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
150000003839 salts Chemical group 0.000 description 6
210000003491 skin Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
101100049203 Bacillus subtilis (strain 168) veg gene Proteins 0.000 description 5
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
108010067902 Peptide Library Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
238000007818 agglutination assay Methods 0.000 description 5
230000003321 amplification Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
239000007850 fluorescent dye Substances 0.000 description 5
238000002372 labelling Methods 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
239000002502 liposome Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
239000011859 microparticle Substances 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 5
238000012552 review Methods 0.000 description 5
108091092562 ribozyme Proteins 0.000 description 5
208000011581 secondary neoplasm Diseases 0.000 description 5
238000000926 separation method Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
238000013519 translation Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
-1 β-D-galactosylkeosin Chemical compound 0.000 description 5
SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 4
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
108010047041 Complementarity Determining Regions Proteins 0.000 description 4
241000287828 Gallus gallus Species 0.000 description 4
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
241000700605 Viruses Species 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
238000000137 annealing Methods 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
210000002798 bone marrow cell Anatomy 0.000 description 4
239000000969 carrier Substances 0.000 description 4
235000013330 chicken meat Nutrition 0.000 description 4
210000004443 dendritic cell Anatomy 0.000 description 4
229940079593 drug Drugs 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
238000000099 in vitro assay Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
239000013642 negative control Substances 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
230000010076 replication Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
230000009261 transgenic effect Effects 0.000 description 4
239000013603 viral vector Substances 0.000 description 4
238000001262 western blot Methods 0.000 description 4
102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 3
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 3
102000000844 Cell Surface Receptors Human genes 0.000 description 3
108010001857 Cell Surface Receptors Proteins 0.000 description 3
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
101150094690 GAL1 gene Proteins 0.000 description 3
102100028501 Galanin peptides Human genes 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 3
101100121078 Homo sapiens GAL gene Proteins 0.000 description 3
101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108020004711 Nucleic Acid Probes Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 3
102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000000556 agonist Substances 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000013602 bacteriophage vector Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
239000002981 blocking agent Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000007910 cell fusion Effects 0.000 description 3
238000012875 competitive assay Methods 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
229910052802 copper Inorganic materials 0.000 description 3
239000010949 copper Substances 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
238000012817 gel-diffusion technique Methods 0.000 description 3
239000005090 green fluorescent protein Substances 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
230000002390 hyperplastic effect Effects 0.000 description 3
230000000951 immunodiffusion Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000003094 microcapsule Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000036963 noncompetitive effect Effects 0.000 description 3
239000002853 nucleic acid probe Substances 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000000816 peptidomimetic Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000013615 primer Substances 0.000 description 3
210000001236 prokaryotic cell Anatomy 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
238000011002 quantification Methods 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
230000001629 suppression Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000008685 targeting Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical class OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 2
RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
FFBLNTOMOSLSQM-AYEYRVMASA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[3-[3-(4-azido-2-nitroanilino)propyl-methylamino]propyl]pentanamide;acetic acid Chemical group CC(O)=O.C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCN(C)CCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O FFBLNTOMOSLSQM-AYEYRVMASA-N 0.000 description 2
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
101150111329 ACE-1 gene Proteins 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
102100026189 Beta-galactosidase Human genes 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
101150008604 CAN1 gene Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
108091005461 Nucleic proteins Chemical class 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
108010066717 Q beta Replicase Proteins 0.000 description 2
108091008103 RNA aptamers Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
101100250396 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL28 gene Proteins 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
108700026226 TATA Box Proteins 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
101100527649 Wickerhamomyces ciferrii (strain ATCC 14091 / BCRC 22168 / CBS 111 / JCM 3599 / NBRC 0793 / NRRL Y-1031 F-60-10) RPL44 gene Proteins 0.000 description 2
FRYWGCQTDZARGT-UHFFFAOYSA-N Wybutoxine Chemical compound O=C1N2C(CC(C(NC(=O)OC)C(=O)OC)OO)=C(C)N=C2N(C)C2=C1NC=N2 FRYWGCQTDZARGT-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000001815 biotherapy Methods 0.000 description 2
210000002459 blastocyst Anatomy 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
210000001840 diploid cell Anatomy 0.000 description 2
208000037765 diseases and disorders Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000002055 immunohistochemical effect Effects 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000004807 localization Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000035168 lymphangiogenesis Effects 0.000 description 2
210000005073 lymphatic endothelial cell Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000005291 magnetic effect Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229960004452 methionine Drugs 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
238000002823 phage display Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 2
238000002005 protein protein interaction detection Methods 0.000 description 2
238000002762 protein-protein interaction assay Methods 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000000163 radioactive labelling Methods 0.000 description 2
239000000376 reactant Substances 0.000 description 2
108091008598 receptor tyrosine kinases Proteins 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
230000010837 receptor-mediated endocytosis Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
210000001533 respiratory mucosa Anatomy 0.000 description 2
230000004044 response Effects 0.000 description 2
102220240796 rs553605556 Human genes 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
230000007017 scission Effects 0.000 description 2
235000020183 skimmed milk Nutrition 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
210000000264 venule Anatomy 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
CADQNXRGRFJSQY-UOWFLXDJSA-N (2r,3r,4r)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
PLAZXGNBGZYJSA-UHFFFAOYSA-N 9-ethylcarbazole Chemical compound C1=CC=C2N(CC)C3=CC=CC=C3C2=C1 PLAZXGNBGZYJSA-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
102100038740 Activator of RNA decay Human genes 0.000 description 1
108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108091032955 Bacterial small RNA Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
102100033040 Carbonic anhydrase 12 Human genes 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
241000905957 Channa melasoma Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
101150075174 E1B gene Proteins 0.000 description 1
108010041308 Endothelial Growth Factors Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
101000933461 Escherichia coli (strain K12) Beta-glucuronidase Proteins 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010058643 Fungal Proteins Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
101150043522 HO gene Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000741919 Homo sapiens Activator of RNA decay Proteins 0.000 description 1
101000867855 Homo sapiens Carbonic anhydrase 12 Proteins 0.000 description 1
101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
101710196632 LexA repressor Proteins 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
231100000070 MTS assay Toxicity 0.000 description 1
238000000719 MTS assay Methods 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
XRYVAQQLDYTHCL-UHFFFAOYSA-N Marini Chemical compound O1C=2C(CC(CC=C(C)C)C(C)=C)=C(O)C=C(O)C=2C(=O)CC1C1=CC=C(O)C=C1O XRYVAQQLDYTHCL-UHFFFAOYSA-N 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
101000783705 Myxoma virus (strain Uriarra) Envelope protein A28 homolog Proteins 0.000 description 1
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000009097 Phosphorylases Human genes 0.000 description 1
108010073135 Phosphorylases Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
206010071019 Prostatic dysplasia Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101150104689 REC102 gene Proteins 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
102000009661 Repressor Proteins Human genes 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
241000220317 Rosa Species 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
101100076570 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MER1 gene Proteins 0.000 description 1
101100033336 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) REC107 gene Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
101150094640 Siae gene Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000251131 Sphyrna Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
241000906446 Theraps Species 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
101710195626 Transcriptional activator protein Proteins 0.000 description 1
102000007238 Transferrin Receptors Human genes 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229940022399 cancer vaccine Drugs 0.000 description 1
238000009566 cancer vaccine Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000002230 centromere Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
210000003711 chorioallantoic membrane Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012504 chromatography matrix Substances 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
238000000749 co-immunoprecipitation Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
108091006047 fluorescent proteins Proteins 0.000 description 1
102000034287 fluorescent proteins Human genes 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
239000003630 growth substance Substances 0.000 description 1
210000003783 haploid cell Anatomy 0.000 description 1
210000003566 hemangioblast Anatomy 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
239000003906 humectant Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000003017 in situ immunoassay Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000000492 lymphangiogenic effect Effects 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000006674 lysosomal degradation Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000009707 neogenesis Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
210000001178 neural stem cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000006959 non-competitive inhibition Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
238000010525 oxidative degradation reaction Methods 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000004091 panning Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
150000008299 phosphorodiamidates Chemical class 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000001855 preneoplastic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000013197 protein A assay Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011472 radical prostatectomy Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000010396 two-hybrid screening Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000006439 vascular pathology Effects 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000009105 vegetative growth Effects 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
235000021247 β-casein Nutrition 0.000 description 1